17
Views
7
CrossRef citations to date
0
Altmetric
Original Article

Treatment of the human retinoblastoma cell line Y-79 growing in the athymic mouse eye with fractionated hyperthermia and/or radiation

&
Pages 203-211 | Received 20 Aug 1988, Accepted 14 Apr 1989, Published online: 09 Jul 2009
 

Abstract

Concentrated cell suspensions of the human retinoblastoma cell line Y-79 were injected into the eyes of athymic nude mice. Three to four weeks after implantation the eyes were treated with fractionated hyperthermia and/or radiation according to various protocols. Radiation was applied with 250 kV X-rays in fractions of 3 Gy, three fractions a week (3×XT). Hyperthermia was applied once a week for 30 min at 43–45°C (1×HT). A coaxial microwave applicator (2450 MHz) has been developed for hyperthermia treatment of the mouse eye. The effect of the treatment was evaluated by visual observation of the eyes during a follow-up of several months, and by histopathological examination. No tumour regression was observed after hyperthermia alone (3×HT). Treatment with 3×XT or 3×XT+1×HT initially caused tumour regression followed by regrowth in most cases. A treatment protocol of 6×XT resulted in regrowth in 10 out of 15 eyes. However, after 6×XT+2×HT regrowth was observed in only 3 out of 13 eyes. The difference between these two groups is statistically significant (P< 0.05). Thus it is concluded that hyperthermia enhances the effect of radiation when the Y-79 cell line is transplanted to the athymic mouse eye, using the fractionation scheme presented here.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.